AptarGroup Inc. reported that its Activ-Film technology was chosen to protect the QuickVue SARS Antigen Test developed by Quidel Corp., which recently received Emergency Use Authorization (EUA) from the U.S. FDA. The visually read test requires no supplemental instrumentation and delivers results in 10 minutes.
Aptar CSP Technologies’ s Activ-Film is integrated into the diagnostic kit to protect against moisture and other environmental conditions that could otherwise impact test accuracy, the company shared in a news release. Activ-Film employs Aptar’s proprietary 3-Phase Activ-Polymer technology, which provides a broad spectrum of custom-engineered protection in a several configurations, such as Activ-Vial for housing diagnostics dipsticks and Activ-Tab integrated within diagnostic cassettes.
"We are pleased to partner with Quidel Corporation on this critical diagnostic tool and help bring the QuickVue SARS Rapid Antigen test to the market,” said Stephan B. Tanda, Aptar president and CEO, in the release. “Our material science Activ-Film technology protects the test strips, helping to provide quick, reliable results to patients, their families and healthcare workers. We will continue to live up to our purpose and responsibility to society by providing solutions that protect critical COVID-19 diagnostic kits, along with dispensing solutions for medicines and consumer products needed by millions of people each day.”
Added Badre Hammond, vice president commercial operations, Aptar CSP Technologies: “As we continue to navigate through the COVID-19 crisis, this game-changing solution will help meet the urgent demand for COVID-19 testing in communities around the world. We are committed to leveraging our material science expertise to enable our partners to meet the ongoing need for innovative healthcare solutions that help improve and save lives.”